PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY

Stefan Schreiber  ¹     Scott Lee  ²     C. Janneke van der Woude  ³     Ignacio Marín-Jiménez  ⁴     Doug Wolf  ⁵     Elisabeth Schnoy  ⁶     Bruce Salzberg  ⁷     Christopher Busse  ⁸     Maciek Nazar  ⁹     Wayne Langholff  ¹⁰     Chris Gasink  ¹⁰     Thomas Baker  ¹⁰     Bridget Godwin  ¹⁰     Joseph Adedokun  ¹⁰     Brian G. Feagan  ^11    
1 Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
² University of Washington, Seattle, United States
³ Erasmus University Medical Center, Rotterdam, Netherlands
⁴ Hospital Universitario Gregorio Marañón, IiSGM, Madrid, Spain
⁵ Atlanta Gastroenterology Associates, Atlanta, United States
⁶ University Hospital of Augsburg, Augsburg, Germany
⁷ IBD Center of Atlanta, Atlanta, United States
⁸ Janssen Scientific Affairs, LLC, Horsham, United States
⁹ Janssen-Cilag Polska Sp. z.o.o., Warsaw, Poland
¹⁰ Janssen Research & Development, LLC, Spring House, United States
¹¹ University of Western Ontario, London, Canada

Topic
IBD

Session
IBD: We treat them all - but how? (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)